Advertisement

Introduction

  • Sadao NagaokaEmail author
Chapter

Abstract

This book provides detailed case studies of 12 groups of 15 major innovative drugs discovered in Japan, and in doing so investigates the sources of their innovations. It discusses: (1) the knowledge sources of the drug-discovery projects; (2) the dynamic interaction between drug discovery and scientific progress; (3) the causes of unexpected difficulties; (4) the capture of serendipity and luck; and (5) the uniqueness and competition of discovery research. The case studies cover the following drugs (generic name of molecules followed by product names): compactin/pravastatin (Mevalotin, Pravachol), rosuvastatin (Crestor), leuprorelin (Leuplin, Leupron, Viadur), ofloxacin (Tarivid, Floxin) and levofloxacin (Cravit, Levaquin), tamsulosin (Harnal, Flomax), pranlukast (Onon), tacrolimus (Prograf), pioglitazone (Actos, Glustin), donepezil (Aricept), candesartan (Blopress, Atacand, Amitas), tocilizumab (Actemra), and nivolumab (Opdivo). It elucidates the concrete mechanism by which science becomes a source of innovation, especially given that science is often incomplete when the discovery project starts. It clarifies the sources and consequences of uncertainties in drug discovery. It expands our understanding of competitive mechanism of drug discovery.

References

  1. Adams, J.D., Clemmons, J.R. (2008). The origins of industrial scientific discovery. National Bureau of Economic Research Working Paper, No. 13823.Google Scholar
  2. Cockburn, I. M., & Henderson, R. (1996). Public-private Interaction in Pharmaceutical Research. Proceedings of the National Academy of Sciences of the United States of America, 93, 12725–12730.CrossRefGoogle Scholar
  3. Cockburn, I. M., & Henderson, R. (2000). Publicly funded science and the productivity of the pharmaceutical industry. Innovation Policy and the Economy, 1, 1–34.CrossRefGoogle Scholar
  4. Zucker G. Z., Darby, M. R., & Brewer, M. B., (1998). Intellectual human capital and the birth of U.S. biotechnology enterprises. American Economic Review, 88(1).Google Scholar
  5. DiMasi, J. A., & Paquette, C. (2004). The economics of follow-on drug research and development: Trends in entry rates and the timing of development. Pharmacoeconomics, 22(2), 1–14.CrossRefGoogle Scholar
  6. Gambardella, A. (1995). Science and innovation: The US pharmaceutical industry during the 1980s. Cambridge University Press.Google Scholar
  7. Kirsch, R. D., & Ogas, Ogi. (2017). The drug hunters: The improbable quest to discover new medicines. New York: Arcade Publishing.Google Scholar
  8. Klevorick, A. K., Levin, R. C., Nelson, R., & Winter, S. (1995). On the sources and significance of inter-industry differences in technological opportunities. Research Policy, 24(2), 185–205.CrossRefGoogle Scholar
  9. Leibenstein, H. (1968). Entrepreneurship and development. The American Economic Review, 56(2), 155–177.Google Scholar
  10. Lichtenberg, F. R., & Philipson, T. (2002). The dual effects of intellectual property regulations: Within- and between-patent competition in the US pharmaceuticals industry. Journal of Law & Economics, 45, 643–672.Google Scholar
  11. Mansfield, E. (1998). Academic research and industrial innovation: An update of empirical findings. Research Policy, 26, 773–776.CrossRefGoogle Scholar
  12. Pisano, G. (2006). Science business: The promise, the reality and the future of biotech. Harvard Business School Press.Google Scholar
  13. Scherer F. M. (2010). Pharmaceutical innovation. In B. H. Hall & N. Rosenberg (Eds.), Handbooks in economics of innovation (Vol. 1), North Holland.Google Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Tokyo Keizai UniversityTokyoJapan

Personalised recommendations